Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas

Constitutive B-cell receptor signaling leads to overexpression of the antiapoptotic BCL-2 protein and is implicated in the pathogenesis of many types of B-cell non-Hodgkin lymphoma (B-NHL). The BCL-2 small-molecule inhibitor venetoclax shows promising clinical response rates in several lymphomas, bu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2017-07, Vol.77 (14), p.3885-3893
Hauptverfasser:	O'Steen, Shyril, Green, Damian J, Gopal, Ajay K, Orozco, Johnnie J, Kenoyer, Aimee L, Lin, Yukang, Wilbur, D Scott, Hamlin, Donald K, Fisher, Darrell R, Hylarides, Mark D, Gooley, Theodore A, Waltman, Amelia, Till, Brian G, Press, Oliver W
Format:	Artikel
Sprache:	eng
Schlagworte:	Animal models Animals Antineoplastic Agents - pharmacology Apoptosis B-cell lymphoma B-cell receptor Bcl-2 protein Bcl-x protein Bridged Bicyclo Compounds, Heterocyclic - pharmacology Cancer CD20 antigen Cell culture Cell death Cell Line, Tumor Cesium Cesium radioisotopes Cesium Radioisotopes - pharmacology Chemoradiotherapy Curing Cytotoxicity DNA damage Female Humans Irradiation Lymphocytes B Lymphoma Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - immunology Lymphoma, B-Cell - radiotherapy Mice Mice, Inbred NOD Proteins Radiation Radiation therapy Radiation Tolerance - drug effects Radioimmunotherapy Sulfonamides - pharmacology Toxicity Toxicity testing Tumor cell lines Xenograft Model Antitumor Assays Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!